c-Abl-p38
Animals
Disease Models, Animal
Dopaminergic Neurons
/ drug effects
Imatinib Mesylate
/ pharmacology
Male
Models, Biological
Neostriatum
/ pathology
Nerve Tissue
/ drug effects
Pain Threshold
/ drug effects
Phosphorylation
/ drug effects
Proto-Oncogene Proteins c-abl
/ metabolism
Rats, Sprague-Dawley
Signal Transduction
/ drug effects
Trigeminal Neuralgia
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ metabolism
Trigeminal neuralgia
c-Abl
dopamine neuron
neuroinflammation
p38
Journal
Molecular pain
ISSN: 1744-8069
Titre abrégé: Mol Pain
Pays: United States
ID NLM: 101242662
Informations de publication
Date de publication:
Historique:
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
4
6
2021
Statut:
ppublish
Résumé
Trigeminal neuralgia is a common neuropathic pain in the head and face. The pathogenesis of trigeminal neuralgia is complex, and so far, the pathogenesis of trigeminal neuralgia involving peripheral and central nervous inflammation theory has not been explained clearly. The loss of dopamine neurons in striatum may play an important role in the development of trigeminal nerve, but the reason is not clear. C-Abl is a nonreceptor tyrosine kinase, which can be activated abnormally in the environment of neuroinflammation and cause neuron death. We found that in the rat model of infraorbital nerve ligation trigeminal neuralgia, the pain threshold decreased, the expression of c-Abl increased significantly, the downstream activation product p38 was also activated abnormally and the loss of dopamine neurons in striatum increased. When treated with imatinib mesylate (STI571), a specific c-Abl family kinase inhibitor, the p38 expression was decreased and the loss of dopaminergic neurons was reduced. The mechanical pain threshold of rats was also improved. In conclusion, c-abl-p38 signaling pathway may play an important role in the pathogenesis of trigeminal neuralgia, and it is one of the potential targets for the treatment of trigeminal neuralgia.
Identifiants
pubmed: 32498644
doi: 10.1177/1744806920930855
pmc: PMC7278317
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Proto-Oncogene Proteins c-abl
EC 2.7.10.2
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1744806920930855Références
Science. 2000 Sep 15;289(5486):1938-42
pubmed: 10988075
Schmerz. 1996 Oct 28;10(5):261-8
pubmed: 12799848
Cell Death Differ. 2016 Mar;23(3):542-52
pubmed: 26517532
Ther Clin Risk Manag. 2015 Feb 24;11:289-99
pubmed: 25750533
Neurosci Lett. 2020 May 29;728:134958
pubmed: 32278943
Mol Pain. 2018 Jan-Dec;14:1744806918756406
pubmed: 29357732
Biol Psychiatry. 2020 Jan 1;87(1):64-73
pubmed: 31806085
Int Rev Neurobiol. 2019;146:259-279
pubmed: 31349930
Exp Hematol. 2000 May;28(5):551-7
pubmed: 10812245
Cephalalgia. 2015 Jan;35(1):16-35
pubmed: 24820887
Br J Neurosurg. 2019 Aug;33(4):409-412
pubmed: 30431370
J Neurosci Res. 2019 Nov 12;:
pubmed: 31721270
Curr Med Chem. 2014;21(38):4405-18
pubmed: 25245374
Br J Anaesth. 2019 Aug;123(2):e385-e396
pubmed: 31208761
J Alzheimers Dis. 2011;25(1):119-33
pubmed: 21368377
J Neurosurg. 2002 Mar;96(3):532-43
pubmed: 11883839
Int J Cell Biol. 2012;2012:683097
pubmed: 22761618
Mol Pain. 2015 Aug 12;11:48
pubmed: 26260484
Neurosurg Rev. 2020 Feb 10;:
pubmed: 32040777
J Biol Chem. 2009 Jun 5;284(23):15469-74
pubmed: 19324872
Pain. 2012 Apr;153(4):744-54
pubmed: 22386471
Nat Rev Neurosci. 2018 Mar;19(3):138-152
pubmed: 29416128
Brain. 2020 Feb 1;143(2):531-540
pubmed: 31930326
Mol Pain. 2019 Jan-Dec;15:1744806919828921
pubmed: 30665329
Brain Behav. 2014 May;4(3):368-80
pubmed: 24944866
J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92
pubmed: 12604685
Brain. 2001 Dec;124(Pt 12):2347-60
pubmed: 11701590
Neurotox Res. 2020 Apr;37(4):800-814
pubmed: 32026358
Mol Pain. 2015 Nov 05;11:68
pubmed: 26542462
Science. 2016 Nov 4;354(6312):572-577
pubmed: 27811267
Am Fam Physician. 2016 Jul 15;94(2):133-5
pubmed: 27419329
Cancer Res. 1974 Sep;34(9):2358-61
pubmed: 4843536
Br J Anaesth. 2019 Nov;123(5):637-654
pubmed: 31551115